Dachaigh › Myasthenia Gravis › California
Sgrùdaidhean clionaigeach Myasthenia Gravis ann an California
Tha 20 sgrùdaidhean airson Myasthenia Gravis a’ lorg phàirtichean aig làraichean ann an California.
Bailtean ann an California
- Orange6 sgrùdaidhean
- San Francisco6 sgrùdaidhean
- Los Angeles4 sgrùdaidhean
- Mountain View4 sgrùdaidhean
- Carlsbad3 sgrùdaidhean
- Pasadena3 sgrùdaidhean
Teacsa sgrùdaidh oifigeil (Beurla)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Neurology Center of North Orange County, Fullerton
- The Neurology Group, Pomona
A’ fastadhÌre 3
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07217587A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Cinical Study Site, Pasadena
A’ fastadhÌre 3
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07647510ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Profound Research LLC - Carlsbad, Carlsbad
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Profound Research LLC - Carlsbad, Carlsbad
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT07284420A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- Tri Valley Neurology Medical Associates Inc., Mission Hills
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT07501702A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, La Jolla
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06680037Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- University of California Irvine Medical Center, Irvine
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Lùna 2026 · NCT06414954A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Stanford Neuroscience Health Center, Palo Alto
A’ fastadhÌre 1
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 14 Lùna 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- University of California Irvine, Orange
- UC Davis, Department of Neurology, Sacramento
- University of California, San Francisco, San Francisco
A’ fastadhÌre 1/2
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 13 Lùna 2026 · NCT06359041Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
- University of California-San Francisco, San Francisco
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 18 gu 64 · Banairean · Air ùrachadh 11 Lùna 2026 · NCT06940323Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Aurinia Investigational Site, Pasadena
A’ fastadhÌre 1/2
Aoisean 18 gu 85 · Gach gnè · Air ùrachadh 3 Lùna 2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- Lucile Packard Children's Hospital Stanford, Palo Alto
- UCSF Benioff Children's Hospital, San Francisco
A’ fastadhÌre 2/3
Aoisean 2 gu 17 · Gach gnè · Air ùrachadh 31 Iuch 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1010, Carlsbad
- Site Number - 1028, Irvine
- Site Number - 1023, Los Angeles
- agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 30 Iuch 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Ronald Reagan UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford University Medical Center, Palo Alto
A’ fastadhÌre 2/3
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 29 Iuch 2026 · NCT06193889A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Care Access Research, Pasadena
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 27 Iuch 2026 · NCT04951622A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- University of Southern California, Los Angeles
- University of California Irvine, Orange
- University of California San Francisco (UCSF), San Francisco
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Ògmh 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford Hospital, Palo Alto
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Gearr 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Fresno
- Clinical Trial Site, Orange
- Clinical Trial Site, Rancho Mirage
- agus 1 a bharrachd
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Gearr 2026 · NCT04202341A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,, San Francisco
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Gearr 2026 · NCT06298565Vitaccess Real MG Registry
- UCI Health, Orange
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Iuch 2025 · NCT06064461Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.